lev-11 Antibody

Target Identification and Isoform Detection

The lev-11 Antibody detects all known isoforms of the LEV-11 tropomyosin protein, including LEV-11A/CeTMI, LEV-11D/CeTMII, and LEV-11E/CeTMIII. Key findings include:

• Alternative splicing: The lev-11 gene produces distinct isoforms through tissue-specific splicing events. For example:

  • LEV-11A/CeTMI (high-molecular-weight isoform) dominates in body wall muscles .

  • LEV-11E/CeTMIII (low-molecular-weight isoform) is prevalent in tissues selecting exon 9a .

• Developmental regulation: LEV-11D/CeTMII, a minor isoform, is expressed during later developmental stages .

Actin-Binding Affinity

The antibody facilitates quantitative analysis of LEV-11 isoform interactions with actin filaments. Data from cosedimentation assays reveal:

These results suggest that specific amino acid substitutions (e.g., E234K) moderately impair actin binding but do not abolish it .

Applications in Disease Models

Though not directly linked to human therapeutics, lev-11 Antibody studies in C. elegans provide foundational insights into:

• Muscle degeneration: Mutations like E234K mimic human tropomyosin-related myopathies .

• Alternative splicing defects: Aberrant isoform ratios correlate with muscle dysfunction .